Prevalence, predictors, and management of advanced HIV disease among individuals initiating ART in Senegal, West Africa

Table 2 Prevalence of advanced HIV disease

	N (%)
All subjects^a, median CD4 cell count (range)	185 (1–1541)
HIV-1 infected^b, median CD4 cell count (range)	170 (1–1541)*
HIV-2 infected, median CD4 cell count (range)	412 (9–1005)*
CD4 cell count categories
≤ 350 cells/mm³	135 (73.0)
< 200 cells/mm³	102 (55.1)
< 100 cells/mm³	67 (36.2)
< 50 cells/mm³	36 (19.5)
WHO stage 3 or 4^c	89 (53.3)
Stage 3 conditions
Severe weight loss	35 (21.2)
Chronic diarrhea	29 (17.6)
Oral candidiasis	28 (17.0)
Oral hairy leukoplakia	5 (3.0)
Pulmonary TB	19 (13.1)
Severe bacterial infections	5 (3.0)
Stage 4 conditions
Wasting	6 (3.6)
PCP	2 (1.2)
Recurrent severe bacterial PNA	2 (1.2)
Esophageal candidiasis	6 (3.6)
Extrapulmonary TB	12 (7.3)
Kaposi sarcoma (cutaneous)	3 (1.8)
Toxoplasmosis	1 (0.6)
Extrapulmonary cryptococcosis	2 (1.2)
Invasive cervical carcinoma	1 (0.6)
CD4 count < 200 cells/mm³ or WHO stage 3 or 4^d	123 (71.1)

^*The difference in CD4 cell counts was statistically significant, p-value = 0.03
^aCD4 cell counts available for 185 subjects
^bIncludes 2 dually infected subjects
^cWHO stage available for 167 subjects; Specific WHO stage 3 or 4 conditions available for 165 subjects
^dData available for 173 subjects

ISSN: 1471-2334